![]() |
![]() |
|
|
||
![]() |
![]() |
|
|
|
Canine Leukocyte Adhesion Deficiency (CLAD) TestFor: Irish Setters and Irish Red & White Setters Please note cheek swabs are not accepted for this test.
CLAD is related to the same disease in humans (LAD) and cattle (BLAD). So far, CLAD has been found only in Irish Setters. Research on the disease was carried out in England and Scandinavia, where the carrier rate is close to 12%. However, CLAD was first identified clinically in the United States. Reliable identification of dogs that do not carry disease genes is the key to eliminating autosomal recessive diseases such as CLAD. Now OptiGen offers a new DNA-based test that provides a method to eliminate Canine Leukocyte Adhesion Deficiency, or CLAD from the Irish Setter. As a mutation-based gene test, the OptiGen CLAD test unequivocally and specifically identifies normal dogs. Called "genetically clear," "noncarriers" or, more formally, "homozygous normals," such dogs can pass only the gene for normal leukocyte (white blood cell) function on to all their pups.
It isn't necessary to remove those carriers which are otherwise excellent dogs from the breeding population. But given the lethal nature of the disease, it is best to select against carriers who are not superlative dogs, so as to entirely eliminate the gene from a line within two or three generations. How you can participate...The rcd1-PRA test and the CLAD test for the Irish Setter are done on a small sample of blood obtained by your veterinarian. This allows the lowest risk of contamination of the sample and added assurance of a match of the sample with the identified dog. No sampling kit is needed. Read and print the instructions on the Ship Sample page. Then fill out the Test Request Form. On-line submission of the Test Request Form lets you be sure accurate information and correct spellings are put in the database. And, when you've completed one Form, a second Test Request Form for another dog or for a litter is easy and saves you time. The research leading to the rcd1-PRA gene test was published in 1994 in Investigative Ophthalmology & Visual Science. The patented technology underlying the CLAD test was discovered by scientists at Uppsala University, Sweden, and is under exclusive license to OptiGen. PCR technology is performed under a license agreement with Roche Molecular Systems, Inc. Latest InformationIrish Red & White Setters – Testing for PRA and CLAD |
|
![]() |
![]() |
|
|
Page last updated June 20, 2011 Copyright 2005 OptiGen · Design and Programming by Spider Graphics Corporation® |
||
![]() |
![]() |